A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)
Latest Information Update: 11 Jun 2025
At a glance
- Drugs TAK 411 (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Proof of concept; Therapeutic Use
- Acronyms CASCA
- Sponsors Takeda
Most Recent Events
- 20 May 2025 Status changed from not yet recruiting to recruiting.
- 14 May 2025 Planned initiation date changed from 30 Apr 2025 to 14 May 2025.
- 01 Apr 2025 Planned initiation date changed from 28 Feb 2025 to 30 Apr 2025.